Antibacterial Activity of Padikara Parpam against ESBL Producing Escherichia coli and Klebsiella pneumoniae

Kasthuri, Revathi and Anthony, Josephine and Akilan, Anitha (2021) Antibacterial Activity of Padikara Parpam against ESBL Producing Escherichia coli and Klebsiella pneumoniae. Journal of Pharmaceutical Research International. pp. 349-354. ISSN 2456-9119

[thumbnail of 34278-Article Text-61635-1-10-20211231.pdf] Text
34278-Article Text-61635-1-10-20211231.pdf - Published Version

Download (548kB)


Aims: To evaluate the antibacterial activity of Padikara Parpam against Extended-Spectrum Beta-Lactamase (ESBL) producing Escherichia Coli and Klebsiella Pneumoniae using agar well diffusion method. To identify ESBL producing bacteria by phenotypic confirmatory test using disk diffusion method.

Study Design: Analysis of Antibacterial activity of Padikara Parpam using agar well diffusion method.

Place and Duration of Study: Central Research Laboratory, Meenakshi Academy of higher Education and Research, Chennai, between June 2021 and November 2021.

Methodology: Clinical isolates of ESBL were isolated by subculture into MacConkey agar and was identified by phenotypic confirmatory test. Padikara parpam's antibacterial activity was evaluated using the Agar well diffusion method at different concentrations of 0.5 %, 1 %, 1.5 %, and 2 % drugs. 30 µg Cefotaxime and 30 µg amoxicillin-clavulanic acid disk were used as controls to standardize the antibacterial activity test and to identify the ESBL by phenotypic confirmatory test.

Results: In this study, Padikara parpam at various doses of 0.5 %, 1 %, 1.5 %, and 2 %, revealed significant antibacterial efficacy against ESBL producing bacteria. Padikara parpam was more active against ESBL Escherichia coli than ESBL Klebsiella pneumoniae. As a result, it may be recommended as an antibacterial agent against ESBL.

Conclusion: Our findings suggest that Siddha Herbo mineral formulations of padikara parpam hold phenomenal antimicrobial activity against ESBL producing bacteria. Based on our findings, the drug may be prescribed successfully for urinary tract infections, which is caused by ESBL producing bacteria.

Item Type: Article
Subjects: Asian Repository > General Subject > Medical Science
0 Subject > Medical Science
Depositing User: Managing Editor
Date Deposited: 13 Jul 2022 11:46
Last Modified: 13 Jul 2022 11:46

Actions (login required)

View Item
View Item